Hemolytic crisis in a patient treated with eculizumab for paroxysmal nocturnal hemoglobinuria possibly triggered by SARS-CoV-2 (COVID-19): a case report
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0584
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Hemolytic crisis in a patient treated with eculizumab for paroxysmal nocturnal hemoglobinuria possibly triggered by SARS-CoV-2 (COVID-19): a case report ; day:10 ; month:11 ; year:2020 ; pages:1-2
Annals of hematology ; (10.11.2020), 1-2
- Classification
-
Medizin, Gesundheit
- Creator
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00277-020-04318-6
- URN
-
urn:nbn:de:101:1-2020122120450438283421
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:23 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Schüller, Hannah
- Klein, Franziska
- Lübbert, Michael
- Prager, Eric Peter
- SpringerLink (Online service)
Other Objects (12)
Hemolytic crisis in a patient treated with eculizumab for paroxysmal nocturnal hemoglobinuria possibly triggered by SARS-CoV-2 (COVID-19): a case report
Eculizumab for paroxysmal nocturnal haemoglobinuria: catastrophic health expenditure in Nepalese patients
AOHE: manuscript AOHE-D-16-00564 paroxysmal nocturnal hemoglobinuria with autoimmune hemolytic anemia following eculizumab therapy—with large granular lymphocytic leukemia
Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria
Hemolytic reaction in the washed salvaged blood of a patient with paroxysmal nocturnal hemoglobinuria
Concomitant Immunosuppressive Therapy and Eculizumab Use in Patients with Paroxysmal Nocturnal Hemoglobinuria: An International PNH Registry Analysis
Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands
Norm-based comparison of the quality-of-life impact of ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria
Paroxysmal nocturnal hemoglobinuria: Where we stand
Neonatal Atypical Hemolytic Uremic Syndrome in the Eculizumab Era
Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use
Use of eculizumab in pregnancy-associated atypical hemolytic uremic syndrome
Hemolytic crisis in a patient treated with eculizumab for paroxysmal nocturnal hemoglobinuria possibly triggered by SARS-CoV-2 (COVID-19): a case report
Eculizumab for paroxysmal nocturnal haemoglobinuria: catastrophic health expenditure in Nepalese patients
AOHE: manuscript AOHE-D-16-00564 paroxysmal nocturnal hemoglobinuria with autoimmune hemolytic anemia following eculizumab therapy—with large granular lymphocytic leukemia
Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria
Hemolytic reaction in the washed salvaged blood of a patient with paroxysmal nocturnal hemoglobinuria
Concomitant Immunosuppressive Therapy and Eculizumab Use in Patients with Paroxysmal Nocturnal Hemoglobinuria: An International PNH Registry Analysis
Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands
Norm-based comparison of the quality-of-life impact of ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria
Paroxysmal nocturnal hemoglobinuria: Where we stand
Neonatal Atypical Hemolytic Uremic Syndrome in the Eculizumab Era
Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use
Use of eculizumab in pregnancy-associated atypical hemolytic uremic syndrome
Hemolytic crisis in a patient treated with eculizumab for paroxysmal nocturnal hemoglobinuria possibly triggered by SARS-CoV-2 (COVID-19): a case report
Eculizumab for paroxysmal nocturnal haemoglobinuria: catastrophic health expenditure in Nepalese patients
AOHE: manuscript AOHE-D-16-00564 paroxysmal nocturnal hemoglobinuria with autoimmune hemolytic anemia following eculizumab therapy—with large granular lymphocytic leukemia
Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria
Hemolytic reaction in the washed salvaged blood of a patient with paroxysmal nocturnal hemoglobinuria
Concomitant Immunosuppressive Therapy and Eculizumab Use in Patients with Paroxysmal Nocturnal Hemoglobinuria: An International PNH Registry Analysis
Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands
Norm-based comparison of the quality-of-life impact of ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria
Paroxysmal nocturnal hemoglobinuria: Where we stand
Neonatal Atypical Hemolytic Uremic Syndrome in the Eculizumab Era
Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use